XML 43 R22.htm IDEA: XBRL DOCUMENT
v3.2.0.727

16. PRO FORMA BALANCE SHEET (UNAUDITED) | 12 Months Ended
--- | ---
Mar. 31, 2015
Notes to Financial Statements |
16. PRO FORMA BALANCE SHEET (UNAUDITED) | Management has presented unaudited pro forma balance sheet information as if the subsequent event discussed below had occurred on March 31, 2015. Such pro forma information is subject to future adjustment as management determines the final accounting for such transaction. June 2015 Financing In June 2015, we sold units (the “Units”), comprised of common stock and warrants, in exchange for net proceeds of $5,591,988, to certain accredited investors, including three institutional investors (collectively the “Purchasers”) at a price of $6.30 per Unit (the “Agreement”). Each Unit consists of one share of common stock and .75 of a five-year warrant to purchase one share of common stock at an exercise price of $6.30 per share. We issued 952,383 shares of common stock and warrants to purchase 714,285 shares of common stock Roth Capital Partners served as placement agent for the transaction and will receive 32,371 warrants for its services as well as a cash commission of $285,512 and $75,000 for its legal expenses in the transaction. We intend to use the proceeds to fund the clinical advancement of the Aethlon Hemopurifier and for general corporate purposes. As part of the terms of the Agreement, we entered into a Registration Rights Agreement with the Purchasers pursuant to which we agreed to file a registration statement to register for resale the shares of common stock issued, as well as the shares of common stock underlying the warrants, within 30 calendar days following the closing of the transaction. Subject to certain exceptions, in the event the registration statement does not become effective within certain time periods set forth in the Registration Rights Agreement, we would be required to pay the Purchasers an amount in cash equal to two percent (2.0%) of the aggregate purchase price of the Units every month until such time as the registration statement becomes effective or the shares of common stock (and shares of common stock underlying the Warrants) sold may be sold by the Purchasers pursuant to Rule 144 without any restrictions or limitations. In connection with the transaction, Mr. James Joyce, our Chief Executive Officer, Mr. James Frakes, our Chief Financial Officer and Dr. Chetan Shah, a director of the Company, each agreed to waive their right to exercise certain stock options and warrants held by them representing the right to acquire 402,318 shares of common stock in the aggregate (the “Waivers”). The Waivers were required in order to make a sufficient number of shares of common stock available for issuance and expire when we amend our Articles of Incorporation to increase sufficiently the number of authorized shares of common stock available for issuance. Pro Forma References The unaudited pro forma balance sheet information as of March 31, 2015 assumes (1) the addition to our cash of $5,591,988 in net proceeds from the June 2015 financing, (2) the issuance of 952,383 shares of our common stock to the Purchasers in the transaction which increases the common stock on our balance sheet by $952, and (3) an increase in our additional paid in capital of $5,591,036. The following unaudited pro forma information has been prepared as though the subsequent event transaction had occurred on March 31, 2015. The pro forma references refer to the above paragraph.
|  | Aethlon Medical, Inc. Consolidated |  |  |  |  |  |  |  | Pro Forma Consolidated |
|  | Balance Sheet |  |  | Pro Forma Adjustments |  | Balance Sheet |
|  | March 31, 2015 |  |  | Amount |  |  | Reference |  | March 31, 2015 |
ASSETS |  |  |  |  |  |  |  |  |  |  |  |  |  |
CURRENT ASSETS |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash |  | $ | 855,596 |  |  | $ | 5,591,988 |  |  | (1) |  | $ | 6,447,584 |
Accounts receivable |  |  | 193,341 |  |  |  | – |  |  |  |  |  | 193,341 |
Deferred financing costs |  |  | 82,324 |  |  |  | – |  |  |  |  |  | 82,324 |
Prepaid expenses |  |  | 73,135 |  |  |  | – |  |  |  |  |  | 73,135 |
TOTAL CURRENT ASSETS |  |  | 1,204,396 |  |  |  | 5,591,988 |  |  | (1) |  |  | 6,796,384 |
NON-CURRENT ASSETS |  |  |  |  |  |  |  |  |  |  |  |  |  |
Property and equipment, net |  |  | 56,091 |  |  |  | – |  |  |  |  |  | 56,091 |
Patents, net |  |  | 103,325 |  |  |  | – |  |  |  |  |  | 103,325 |
Deposits |  |  | 16,776 |  |  |  | – |  |  |  |  |  | 16,776 |
TOTAL NONCURRENT ASSETS |  |  | 176,192 |  |  |  | – |  |  |  |  |  | 176,192 |
TOTAL ASSETS |  | $ | 1,380,588 |  |  | $ | 5,591,988 |  |  | (1) |  | $ | 6,972,576 |
LIABILITIES AND DEFICIT |  |  |  |  |  |  |  |  |  |  |  |  |  |
CURRENT LIABILITIES |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  | $ | 342,133 |  |  | $ | – |  |  |  |  | $ | 342,133 |
Due to related parties |  |  | 146,112 |  |  |  |  |  |  |  |  |  | 146,112 |
Other current liabilities |  |  | 85,731 |  |  |  | – |  |  |  |  |  | 85,731 |
TOTAL CURRENT LIABILITIES |  |  | 573,976 |  |  |  | – |  |  |  |  |  | 573,976 |
NONCURRENT LIABILITIES |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible notes payable, non-current portion |  |  | 155,229 |  |  |  | – |  |  |  |  |  | 155,229 |
TOTAL NONCURRENT LIABILITIES |  |  | 155,229 |  |  |  | – |  |  |  |  |  | 155,229 |
TOTAL LIABILITIES |  |  | 729,205 |  |  |  | – |  |  |  |  |  | 729,205 |
COMMITMENTS AND CONTINGENCIES |  |  |  |  |  |  |  |  |  |  |  |  |  |
STOCKHOLDERS' EQUITY |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock |  |  | 6,657 |  |  |  | 952 |  |  | (2) |  |  | 7,609 |
Additional paid in capital |  |  | 82,238,507 |  |  |  | 5,591,036 |  |  | (3) |  |  | 87,829,543 |
Accumulated deficit |  |  | (81,629,714 | ) |  |  | – |  |  | - |  |  | (81,629,714 | )
TOTAL AETHLON MEDICAL, INC. STOCKHOLDERS' EQUITY |  |  | 615,450 |  |  |  | 5,591,988 |  |  | (2) (3) |  |  | 6,207,438 |
Noncontrolling interests |  |  | 35,933 |  |  |  | – |  |  |  |  |  | 35,933 |
TOTAL EQUITY |  |  | 651,383 |  |  |  | 5,591,988 |  |  | (2) (3) |  |  | 6,243,371 |
TOTAL LIABILITIES AND EQUITY |  | $ | 1,380,588 |  |  | $ | 5,591,988 |  |  | (2) (3) |  | $ | 6,972,576 |

X
- References No definition available. + Details
Name: | aemd_NotesToFinancialStatementsAbstract
Namespace Prefix: | aemd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting accounting changes, excludes error corrections information. + References No definition available. + Details
Name: | us-gaap_AccountingChangesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration